Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 11;15(1):12495.
doi: 10.1038/s41598-025-91575-y.

Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images

Affiliations

Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images

Jiameng Lu et al. Sci Rep. .

Abstract

Radiomics refers to the utilization of automated or semi-automated techniques to extract and analyze numerous quantitative features from medical images, such as computerized tomography (CT) or magnetic resonance imaging (MRI) scans. This study aims to develop a deep learning radiomics (DLR)-based approach for predicting programmed death-ligand 1 (PD-L1) expression in patients with non-small cell lung cancer (NSCLC). Data from 352 NSCLC patients with known PD-L1 expression were collected, of which 48.29% (170/352) were tested positive for PD-L1 expression. Tumor regions of interest (ROI) were semi-automatically segmented based on CT images, and DL features were extracted using Residual Network 50. The least absolute shrinkage and selection operator (LASSO) algorithm was used for feature selection and dimensionality reduction. Seven algorithms were used to build models, and the most optimal ones were identified. A combined model integrating DLR with clinical data was also developed. The predictive performance of each model was evaluated using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve analysis. The DLR model, based on CT images, demonstrated an AUC of 0.85 (95% confidence interval (CI), 0.82-0.88), sensitivity of 0.80 (0.74-0.85), and specificity of 0.73 (0.70-0.77) for predicting PD-L1 status. The integrated model exhibited superior performance, with an AUC of 0.91 (0.87-0.95), sensitivity of 0.85 (0.82-0.89), and specificity of 0.75 (0.72-0.80). Our findings indicate that the DLR model holds promise as a valuable tool for predicting the PD-L1 status in patients with NSCLC, which can greatly assist in clinical decision-making and the selection of personalized treatment strategies.

Keywords: Deep learning; Non-small cell lung cancer (NSCLC); Programmed death-ligand 1(PD-L1)..

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: The studies involving human participants underwent a thorough review and received approval from the Institutional Review Committee of the First Affiliated Hospital of Shandong First Medical University (Jinan, China). Consent: The informed consent was waived by the First Affiliated Hospital of Shandong First Medical University. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of NSCLC patient selection.
Fig. 2
Fig. 2
Workflow of the DLR analysis.
Fig. 3
Fig. 3
Selection of radiomics features. The LASSO was used to filter the most relevant features. (A) Selection of tuning parameter (λ). (B) Coefficient of each selected feature. LASSO: least absolute shrinkage and selection operator, MSE: mean square error.
Fig. 4
Fig. 4
ROC curves for the DLR models and the combined model in predicting the expression statuses of PD-L1. (A) ROC curves for the DLR models. (B) ROC curve for the combined model.
Fig. 5
Fig. 5
Visualization of 2 patient examples. Each example displays a gray-scale CT image alongside its corresponding heat map. Within these heat maps, the red region signifies a higher weight, which can be interpreted using the color bar located on the right-hand side.

Similar articles

Cited by

References

    1. Prevalence and attributable health burden of chronic respiratory diseases. 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med.8(6), 585–596 (2020). - PMC - PubMed
    1. Feng, P. et al. Application of diffusion kurtosis imaging and (18)F-FDG PET in evaluating the subtype, stage and proliferation status of non-small cell lung cancer. Front. Oncol.12, 989131 (2022). - PMC - PubMed
    1. Loh, J. et al. Management of oncogene driven locally advanced unresectable non-small cell lung cancer. Expert Rev. Anticancer Ther.23(9), 913–926 (2023). - PubMed
    1. Rizvi, N. A. et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol.34(25), 2969–2979 (2016). - PMC - PubMed
    1. Ettinger, D. S. et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J. Natl. Compr. Canc Netw.19(3), 254–266 (2021). - PubMed